← Back to Companies

Stoke Therapeutics

Biotechnology company developing antisense oligonucleotide (ASO) therapies to upregulate protein expression for haploinsufficiency diseases. Publicly traded on NASDAQ (STOK). Lead program targets Dravet syndrome.

Location
Bedford, Massachusetts, USA
Founded
2014
Investors
1
Categories
biotech, therapeutics, rna, rare-disease, public-company

Notes

Stoke Therapeutics is a biotechnology company developing antisense oligonucleotide (ASO) therapies to treat diseases caused by haploinsufficiency - conditions where one copy of a gene is mutated and the remaining functional copy doesn't produce enough protein. The company is publicly traded on NASDAQ under the ticker symbol STOK.

The company's TANGO (Targeted Augmentation of Nuclear Gene Output) platform uses ASOs to increase protein expression from the healthy copy of a gene. This approach is particularly relevant for rare genetic diseases where patients have one functional gene copy.

Stoke's lead program, STK-001, is being developed for Dravet syndrome, a severe form of epilepsy caused by mutations in the SCN1A gene.

Team

  • Ed Bhardwaj - Chief Executive Officer
  • Huw Nash, Ph.D. - Chief Scientific Officer
  • Adrian Bhardwaj - Co-founder

Additional Research Findings

  • NASDAQ: STOK (publicly traded)
  • TANGO platform for haploinsufficiency diseases
  • Antisense oligonucleotide (ASO) technology
  • Lead program: STK-001 for Dravet syndrome
  • Bedford, Massachusetts headquarters
  • Founded in 2014
  • Focus on rare genetic diseases

Sources

Investors

NameLocationTypeStagesPortfolio
Apple Tree PartnersNew York, USAbiotech-focused
series-aseries-b+2
23